

Resolvin E1 Improves Tear Production and Decreases Inflammation in a Dry Eye Disease Model

Journal of Ocular Pharmacology and Therapeutics

26, 431-439

DOI: [10.1089/jop.2010.0019](https://doi.org/10.1089/jop.2010.0019)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Resolvins and Protectins in Inflammation Resolution. <i>Chemical Reviews</i> , 2011, 111, 5922-5943.	23.0	823
2	Docosahexaenoic acid, protectins and dry eye. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2011, 14, 132-137.	1.3	46
3	Controlling Herpes Simplex Virus-Induced Ocular Inflammatory Lesions with the Lipid-Derived Mediator Resolvin E1. <i>Journal of Immunology</i> , 2011, 186, 1735-1746.	0.4	125
4	Specialized proresolving mediator targets for RvE1 and RvD1 in peripheral blood and mechanisms of resolution. <i>Biochemical Journal</i> , 2011, 437, 185-197.	1.7	125
5	Dry Eye Disease. <i>JAMA Ophthalmology</i> , 2012, 130, 90.	2.6	464
6	Immunomodulation of microglia by docosahexaenoic acid and eicosapentaenoic acid. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2012, 15, 1.	1.3	22
7	Resolvin D1 prevents TNF- α -mediated disruption of salivary epithelial formation. <i>American Journal of Physiology - Cell Physiology</i> , 2012, 302, C1331-C1345.	2.1	80
8	Pro-Resolving Lipid Mediators (SPMs) and Their Actions in Regulating miRNA in Novel Resolution Circuits in Inflammation. <i>Frontiers in Immunology</i> , 2012, 3, 298.	2.2	118
9	Resolvin E1 (RX-10001) Reduces Corneal Epithelial Barrier Disruption and Protects Against Goblet Cell Loss in a Murine Model of Dry Eye. <i>Cornea</i> , 2012, 31, 1299-1303.	0.9	78
10	Selenium Compound Protects Corneal Epithelium against Oxidative Stress. <i>PLoS ONE</i> , 2012, 7, e45612.	1.1	52
11	Use of mini scleral contact lenses in moderate to severe dry eye. <i>Contact Lens and Anterior Eye</i> , 2012, 35, 272-276.	0.8	63
12	Resolvins: Anti-Inflammatory and Proresolving Mediators Derived from Omega-3 Polyunsaturated Fatty Acids. <i>Annual Review of Nutrition</i> , 2012, 32, 203-227.	4.3	147
13	Therapeutic potential of resolvins in the prevention and treatment of inflammatory disorders. <i>Biochemical Pharmacology</i> , 2012, 84, 1340-1350.	2.0	53
14	Resolvins as new fascinating drug candidates for inflammatory diseases. <i>Archives of Pharmacal Research</i> , 2012, 35, 3-7.	2.7	66
15	Omega-3 fatty acids and their lipid mediators: Towards an understanding of resolvin and protectin formation. <i>Prostaglandins and Other Lipid Mediators</i> , 2012, 97, 73-82.	1.0	218
16	Polyunsaturated fatty acids induce modification in the lipid composition and the prostaglandin production of the conjunctival epithelium cells. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2012, 250, 211-222.	1.0	5
17	Natural resolution of inflammation. <i>Periodontology 2000</i> , 2013, 63, 149-164.	6.3	271
18	Changing trends in the treatment of dry-eye disease. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 1581-1601.	1.9	48

#	ARTICLE	IF	CITATIONS
19	Diet, nutraceuticals and the tear film. <i>Experimental Eye Research</i> , 2013, 117, 138-146.	1.2	33
20	New Agents for Treating Dry Eye Syndrome. <i>Current Allergy and Asthma Reports</i> , 2013, 13, 322-328.	2.4	16
21	Involvement of pigment epithelium-derived factor, docosahexaenoic acid and neuroprotectin D1 in corneal inflammation and nerve integrity after refractive surgery. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2013, 88, 27-31.	1.0	26
22	Emerging drugs for the treatment of dry eye disease. <i>Expert Opinion on Emerging Drugs</i> , 2013, 18, 121-136.	1.0	8
23	DHA, EPA, and Ocular Health. , 2013, , 89-101.		0
24	Resolution of inflammation: Mechanisms and opportunity for drug development. , 2013, 139, 189-212.		183
25	Resolvin D1 and its GPCRs in resolution circuits of inflammation. <i>Prostaglandins and Other Lipid Mediators</i> , 2013, 107, 64-76.	1.0	40
26	Resolvin D1 and aspirin-triggered resolvin D1 regulate histamine-stimulated conjunctival goblet cell secretion. <i>Mucosal Immunology</i> , 2013, 6, 1119-1130.	2.7	76
27	Patients undergoing long-term treatment with antihypertensive eye drops responded positively with respect to their ocular surface disorder to oral supplementation with antioxidants and essential fatty acids. <i>Clinical Interventions in Aging</i> , 2013, 8, 711.	1.3	41
28	Effects of a nutraceutical formulation based on the combination of antioxidants and ω -3 essential fatty acids in the expression of inflammation and immune response mediators in tears from patients with dry eye disorders. <i>Clinical Interventions in Aging</i> , 2013, 8, 139.	1.3	73
29	Rethinking Dry Eye Disease: A Perspective on Clinical Implications. <i>Ocular Surface</i> , 2014, 12, S1-S31.	2.2	189
30	Intracanal Delivery of Resolvin E1 Controls Inflammation in Necrotic Immature Rat Teeth. <i>Journal of Endodontics</i> , 2014, 40, 678-682.	1.4	17
31	Potential for daily supplementation of n-3 fatty acids to reverse symptoms of dry eye in mice. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2014, 90, 207-213.	1.0	10
32	Effect of the pro-resolution lipid mediator resolvin E1 (RvE1) on pulp tissues exposed to the oral environment. <i>International Endodontic Journal</i> , 2014, 47, 827-834.	2.3	12
33	Expression of Resolvin D1 Biosynthetic Pathways in Salivary Epithelium. <i>Journal of Dental Research</i> , 2014, 93, 300-305.	2.5	25
34	Effects of Eye Drops Containing a Mixture of Omega-3 Essential Fatty Acids and Hyaluronic Acid on the Ocular Surface in Desiccating Stress-induced Murine Dry Eye. <i>Current Eye Research</i> , 2014, 39, 871-878.	0.7	49
35	Dry eye disease: A review of diagnostic approaches and treatments. <i>Saudi Journal of Ophthalmology</i> , 2014, 28, 173-181.	0.3	67
36	Anti-inflammatory effects of resolvin-D1 on human corneal epithelial cells: in vitro study. <i>Journal of Inflammation</i> , 2014, 11, 6.	1.5	24

#	ARTICLE	IF	CITATIONS
37	ALX/FPR2 receptor for RvD1 is expressed and functional in salivary glands. American Journal of Physiology - Cell Physiology, 2014, 306, C178-C185.	2.1	46
38	Omegeas and Dry Eye. Optometry and Vision Science, 2015, 92, 948-956.	0.6	29
39	New drugs for the treatment of dry eye disease. Clinical Optometry, 2015, , 91.	0.4	7
40	Interaction Studies of Resolvin E1 Analog (RX-10045) with Efflux Transporters. Journal of Ocular Pharmacology and Therapeutics, 2015, 31, 248-255.	0.6	13
41	InÂvitro effects of docosahexaenoic and eicosapentaenoic acid on human meibomian gland epithelial cells. Experimental Eye Research, 2015, 140, 139-148.	1.2	30
42	Lipid-Based Therapy for Ocular Surface Inflammation and Disease. Trends in Molecular Medicine, 2015, 21, 736-748.	3.5	33
43	Roles of resolvins in the resolution of acute inflammation. Cell Biology International, 2015, 39, 3-22.	1.4	45
44	Neuropathic ocular pain: an important yet underevaluated feature of dry eye. Eye, 2015, 29, 301-312.	1.1	171
45	Lipid Mediators in the Resolution of Inflammation. Cold Spring Harbor Perspectives in Biology, 2015, 7, a016311.	2.3	389
46	Resolvins and aliamides: lipid autacoids in ophthalmology – what promise do they hold?. Drug Design, Development and Therapy, 2016, Volume 10, 3133-3141.	2.0	17
47	Ï‰-3 Tear Film Lipids Correlate With Clinical Measures of Dry Eye. , 2016, 57, 2472.		60
48	Lipoxins, Resolvins, and the Resolution of Inflammation. , 2016, , 211-239.		2
49	Specialized pro-resolving mediators: endogenous regulators of infection and inflammation. Nature Reviews Immunology, 2016, 16, 51-67.	10.6	479
50	Topical delivery of aqueous micellar resolvin E1 analog (RX-10045). International Journal of Pharmaceutics, 2016, 498, 326-334.	2.6	40
51	A semifluorinated alkane (F4H5) as novel carrier for cyclosporine A: a promising therapeutic and prophylactic option for topical treatment of dry eye. Graefe's Archive for Clinical and Experimental Ophthalmology, 2017, 255, 767-775.	1.0	20
52	Ocular Effects of Sulfur Mustard and Therapeutic Approaches. Journal of Cellular Biochemistry, 2017, 118, 3549-3560.	1.2	26
53	Treating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms. FASEB Journal, 2017, 31, 1273-1288.	0.2	437
54	Discovery of specialized pro-resolving mediators marks the dawn of resolution physiology and pharmacology. Molecular Aspects of Medicine, 2017, 58, 1-11.	2.7	188

#	ARTICLE	IF	CITATIONS
55	Current and emerging therapy of dry eye disease. Part A: pharmacological modalities. Expert Review of Ophthalmology, 2017, 12, 269-297.	0.3	4
56	The role of pro-resolving lipid mediators in ocular diseases. Molecular Aspects of Medicine, 2017, 58, 37-43.	2.7	19
57	The role of systemic and topical fatty acids for dry eye treatment. Progress in Retinal and Eye Research, 2017, 61, 23-34.	7.3	40
58	Recovery of Corneal Sensitivity and Increase in Nerve Density and Wound Healing in Diabetic Mice After PEDF Plus DHA Treatment. Diabetes, 2017, 66, 2511-2520.	0.3	53
59	The role of dyslipidemia in diabetic retinopathy. Vision Research, 2017, 139, 228-236.	0.7	70
60	Structural elucidation and physiologic functions of specialized pro-resolving mediators and their receptors. Molecular Aspects of Medicine, 2017, 58, 114-129.	2.7	255
61	Omega-3 supplementation is neuroprotective to corneal nerves in dry eye disease: a pilot study. Ophthalmic and Physiological Optics, 2017, 37, 473-481.	1.0	54
62	Defining a mechanistic link between pigment epithelium-derived factor, docosahexaenoic acid, and corneal nerve regeneration. Journal of Biological Chemistry, 2017, 292, 18486-18499.	1.6	50
63	TFOS DEWS II Management and Therapy Report. Ocular Surface, 2017, 15, 575-628.	2.2	839
64	Atherosclerosis, Periodontal Disease, and Treatment with Resolvins. Current Atherosclerosis Reports, 2017, 19, 57.	2.0	37
65	Pro-Resolution Potency of Resolvins D1, D2 and E1 on Neutrophil Migration and in Dermal Wound Healing. Nano LIFE, 2017, 07, 1750002.	0.6	20
66	Analysis of the Pathogenic Factors and Management of Dry Eye in Ocular Surface Disorders. International Journal of Molecular Sciences, 2017, 18, 1764.	1.8	30
67	Paradigm shift – Metabolic transformation of docosahexaenoic and eicosapentaenoic acids to bioactives exemplify the promise of fatty acid drug discovery. Biotechnology Advances, 2018, 36, 935-953.	6.0	27
68	Signaling pathways activated by resolvin E1 to stimulate mucin secretion and increase intracellular Ca ²⁺ in cultured rat conjunctival goblet cells. Experimental Eye Research, 2018, 173, 64-72.	1.2	14
69	Beneficial effect of daidzin in dry eye rat model through the suppression of inflammation and oxidative stress in the cornea. Saudi Journal of Biological Sciences, 2018, 25, 832-837.	1.8	21
70	New pro-resolving n-3 mediators bridge resolution of infectious inflammation to tissue regeneration. Molecular Aspects of Medicine, 2018, 64, 1-17.	2.7	186
71	Corneal Blindness Caused by Mustard Gas. , 0, , .		0
72	Immunoregulatory role of 15-lipoxygenase in the pathogenesis of bacterial keratitis. FASEB Journal, 2018, 32, 5026-5038.	0.2	13

#	ARTICLE	IF	CITATIONS
73	Neuroinflammatory pathways as treatment targets and biomarkers in epilepsy. <i>Nature Reviews Neurology</i> , 2019, 15, 459-472.	4.9	463
74	Resolvin E1 Ameliorates Pulpitis by Suppressing Dental Pulp Fibroblast Activation in a Chemerin Receptor 23-dependent Manner. <i>Journal of Endodontics</i> , 2019, 45, 1126-1134.e1.	1.4	20
75	Dry Eye Disease and Essential Fatty Acids. , 2019, , 321-331.		0
76	Resolvin D2 elevates cAMP to increase intracellular [Ca ²⁺] and stimulate secretion from conjunctival goblet cells. <i>FASEB Journal</i> , 2019, 33, 8468-8478.	0.2	15
77	Omega-3 and omega-6 polyunsaturated fatty acids for dry eye disease. <i>The Cochrane Library</i> , 2019, 12, CD011016.	1.5	42
78	Efficacy of Omega-3 Fatty Acid Supplementation for Treatment of Dry Eye Disease: A Meta-Analysis of Randomized Clinical Trials. <i>Cornea</i> , 2019, 38, 565-573.	0.9	81
79	VIP modulates the ALX/FPR2 receptor axis toward inflammation resolution in a mouse model of bacterial keratitis. <i>Prostaglandins and Other Lipid Mediators</i> , 2019, 140, 18-25.	1.0	10
80	Profile of tear lipid mediator as a biomarker of inflammation for meibomian gland dysfunction and ocular surface diseases: Standard operating procedures. <i>Ocular Surface</i> , 2022, 26, 318-327.	2.2	9
81	Chronic Tear Deficiency Sensitizes Transient Receptor Potential Vanilloid 1-Mediated Responses in Corneal Sensory Nerves. <i>Frontiers in Cellular Neuroscience</i> , 2020, 14, 598678.	1.8	15
82	Omega-3 derivatives, specialized pro-resolving mediators: Promising therapeutic tools for the treatment of pain in chronic liver disease. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2020, 158, 102095.	1.0	12
83	Leukotriene B4 receptors as therapeutic targets for ophthalmic diseases. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2020, 1865, 158756.	1.2	2
84	The Role of Nutrition and Nutritional Supplements in Ocular Surface Diseases. <i>Nutrients</i> , 2020, 12, 952.	1.7	46
85	The potential of lipid mediator networks as ocular surface therapeutics and biomarkers. <i>Ocular Surface</i> , 2021, 19, 104-114.	2.2	13
86	Modern approach to the treatment of dry eye, a complex multifactorial disease: a P.I.C.A.S.S.O. board review. <i>British Journal of Ophthalmology</i> , 2021, 105, 446-453.	2.1	81
87	Clinical influence of calcium hydroxide and N-acetylcysteine on the levels of resolvins E1 and D2 in apical periodontitis. <i>International Endodontic Journal</i> , 2021, 54, 61-73.	2.3	9
88	Overview of Polyphenols and Polyphenol-rich Extracts as Modulators of Inflammatory Response in Dry Eye Syndrome. <i>Food Reviews International</i> , 2022, 38, 501-528.	4.3	4
89	Experimental Pharmacotherapy for Dry Eye Disease: A Review. <i>Journal of Experimental Pharmacology</i> , 2021, Volume 13, 345-358.	1.5	19
90	The Protective Effect of Polyunsaturated Fatty Acids against Dry Eye Disease: A Literature Review. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 4519.	1.3	3

#	ARTICLE	IF	CITATIONS
91	Differentially Expressed Gene Pathways in the Conjunctiva of Sjögren Syndrome Keratoconjunctivitis Sicca. <i>Frontiers in Immunology</i> , 2021, 12, 702755.	2.2	13
92	Harnessing Inflammation Resolution in Arthritis: Current Understanding of Specialized Pro-resolving Lipid Mediators's Contribution to Arthritis Physiopathology and Future Perspectives. <i>Frontiers in Physiology</i> , 2021, 12, 729134.	1.3	11
93	Macrophages and the Entrance of Resolution Phase Lipid Mediators. , 2014, , 287-314.		3
94	Transduced PEP-1-FK506BP ameliorates corneal injury in Botulinum toxin A-induced dry eye mouse model. <i>BMB Reports</i> , 2013, 46, 124-129.	1.1	22
95	Okuläre Oberfläche "nicht infektiös". , 2014, , 117-180.		0
96	New Agents for Treating Dry Eye Syndrome. <i>Oxidative Stress in Applied Basic Research and Clinical Practice</i> , 2015, , 115-129.	0.4	1
97	Dry eye: an inflammatory ocular disease. <i>Journal of Ophthalmic and Vision Research</i> , 2014, 9, 240-50.	0.7	116
98	Resolvin E1 analog RX-10045 0.1% reduces corneal stromal haze in rabbits when applied topically after PRK. <i>Molecular Vision</i> , 2014, 20, 1710-6.	1.1	11
99	Evaluation of treatment for dry eye with 2-hydroxyestradiol using a dry eye rat model. <i>Molecular Vision</i> , 2016, 22, 446-53.	1.1	6
100	Regulation of T-Cell Immune Responses by Pro-Resolving Lipid Mediators. <i>Frontiers in Immunology</i> , 2021, 12, 768133.	2.2	21
102	The utilisation of resolvins in medicine and tissue engineering. <i>Acta Biomaterialia</i> , 2022, 140, 116-135.	4.1	7
103	Immune regulation of the ocular surface. <i>Experimental Eye Research</i> , 2022, 218, 109007.	1.2	17
105	High-Fat Nutritional Challenge Reshapes Circadian Signatures in Murine Extraorbital Lacrimal Glands. , 2022, 63, 23.		5
106	Topical Omega-3 Fatty Acids Eyedrops in the Treatment of Dry Eye and Ocular Surface Disease: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13156.	1.8	3
107	Omega-3 polyunsaturated fatty acids and corneal nerve health: Current evidence and future directions. <i>Ocular Surface</i> , 2023, 27, 1-12.	2.2	7
108	Serum Maresin 1 levels in idiopathic acute anterior uveitis patients. <i>Journal Francais D'Ophthalmologie</i> , 2022, , .	0.2	0
109	Ocular surface immune cell diversity in dry eye disease. <i>Indian Journal of Ophthalmology</i> , 2023, 71, 1237-1247.	0.5	1